Epic Sciences Raises $13M, Advances Ultra-Sensitive Cell Diagnostics
(Page 2 of 2)
turn cancer into a chronic-but-manageable disease—much like current treatment of HIV.
Domain partner Kim Kamdar, who is joining Epic’s board, is quoted in the statement as saying, “We see that Epic’s technology will not only have a major impact on clinical cancer treatments but also on the development of new cancer therapeutics and companion diagnostics.”
The company, which now has 25 employees and is growing fast, has been conducting more than 12 early stage clinical trials of the technology with seven pharmaceutical partners, Nelson says. The Phase I and II clinical trials, which will ultimately involve more than 1,500 patients, are intended to combine Epic’s diagnostics technology with specific anti-cancer compounds to create companion diagnostic products for each oncology drug.
Proceeds of the venture funding will be used to get “commercial ready for these diagnostics as they move through the pipeline,” Nelson says. The company would need FDA approval for each companion diagnostic application.
[Corrected to show TSRI's Peter Kuhn, not Epic Sciences, has been working with Eric Topol.] The company sees applications beyond cancer as well, Nelson says. For example, Scripps’ Kuhn has been working with the cardiologist Eric Topol, director of the Scripps Translational Science Institute and chief academic officer at Scripps Health, to detect a specific type of endothelial cell that is sloughed off before a heart attack.